1 1976 01 16 2019 02 08

0006-2944 13 2 1975 Jun Biochem Med Formate assay in body fluids: application in methanol poisoning. 117-26 Makar A B AB McMartin K E KE Palese M M Tephly T R TR eng MC_UU_12013/5 MRC United Kingdom Journal Article Research Support, U.S. Gov't, P.H.S.

United States Biochem Med 0151424 0006-2944 0 Formates 142M471B3J Carbon Dioxide EC 1.2.- Aldehyde Oxidoreductases Y4S76JWI15 Methanol IM Aldehyde Oxidoreductases metabolism Animals Body Fluids analysis Carbon Dioxide blood Formates blood poisoning Haplorhini Humans Hydrogen-Ion Concentration Kinetics Methanol blood Methods Pseudomonas enzymology 1975 6 1 1975 6 1 0 1 1975 6 1 0 0 ppublish 1 10.1016/0006-2944(75)90147-7 2 1976 01 10 2019 06 12

1090-2104 66 4 1975 Oct 27 Biochem Biophys Res Commun Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution. 1173-9 Bose K S KS Sarma R H RH eng Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

United States Biochem Biophys Res Commun 0372516 0006-291X 0U46U6E8UK NAD 53-59-8 NADP IM Biochem Pharmacol. 1975 Aug 15;24(16):1517-21 8 Fourier Analysis Magnetic Resonance Spectroscopy Models, Molecular Molecular Conformation NAD analogs & derivatives NADP Structure-Activity Relationship Temperature 1975 10 27 1975 10 27 0 1 1975 10 27 0 0 ppublish 2 0006-291X(75)90482-9 10.1016/0006-291x(75)90482-9 3 1976 01 10 2019 06 12

0006-291X 66 4 1975 Oct 27 Biochem Biophys Res Commun Metal substitutions incarbonic anhydrase: a halide ion probe study. 1281-6 Smith R J RJ Bryant R G RG eng Journal Article Research Support, U.S. Gov't, P.H.S.

United States Biochem Biophys Res Commun 0372516 0006-291X 00BH33GNGH Cadmium EC 4.2.1.1 Carbonic Anhydrases FXS1BY2PGL Mercury J41CSQ7QDS Zinc IM Animals Binding Sites Cadmium Carbonic Anhydrases metabolism Cattle Humans Hydrogen-Ion Concentration Magnetic Resonance Spectroscopy Mercury Protein Binding Protein Conformation Zinc pharmacology 1975 10 27 1975 10 27 0 1 1975 10 27 0 0 ppublish 3 0006-291X(75)90498-2 10.1016/0006-291x(75)90498-2 4 1976 01 10 2019 06 12

1090-2104 66 4 1975 Oct 27 Biochem Biophys Res Commun Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. 1338-43 Wiesmann U N UN DiDonato S S Herschkowitz N N NN eng BB/C008219/1 Biotechnology and Biological Sciences Research Council United Kingdom G1100377 Medical Research Council United Kingdom G1100377 MRC United Kingdom Journal Article

United States Biochem Biophys Res Commun 0372516 0006-291X 0 Dextrans 886U3H6UFF Chloroquine EC 3.1.6.- Sulfatases EC 3.1.6.8 Cerebroside-Sulfatase EC 3.2.1.31 Glucuronidase IM Biological Transport Cells, Cultured Cerebroside-Sulfatase metabolism Chloroquine pharmacology Dextrans metabolism Fibroblasts enzymology metabolism Glucuronidase metabolism Humans Leukodystrophy, Metachromatic enzymology Lysosomes drug effects enzymology Pinocytosis drug effects Skin enzymology Sulfatases metabolism 1975 10 27 1975 10 27 0 1 1975 10 27 0 0 ppublish 4 0006-291X(75)90506-9 10.1016/0006-291x(75)90506-9 5 1976 01 10 2019 06 12

1090-2104 66 4 1975 Oct 27 Biochem Biophys Res Commun Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin. 1349-56 Hendrickson W A WA Ward K B KB eng Journal Article

United States Biochem Biophys Res Commun 0372516 0006-291X 0 Hemerythrin 0 Metalloproteins 0 Muscle Proteins IM Animals Cnidaria Computers Hemerythrin Metalloproteins Models, Molecular Muscle Proteins Protein Conformation Species Specificity 1975 10 27 1975 10 27 0 1 1975 10 27 0 0 ppublish 5 0006-291X(75)90508-2 10.1016/0006-291x(75)90508-2 6 1976 01 10 2019 06 12

0006-291X 66 4 1975 Oct 27 Biochem Biophys Res Commun Studies of oxygen binding energy to hemoglobin molecule. 1424-31 Chow Y W YW Pietranico R R Mukerji A A eng Journal Article Research Support, U.S. Gov't, Non-P.H.S.

United States Biochem Biophys Res Commun 0372516 0006-291X 0 Hemoglobins 0 Ligands 0 Oxyhemoglobins 3G0H8C9362 Cobalt E1UOL152H7 Iron S88TT14065 Oxygen IM Binding Sites Cobalt blood Hemoglobins Humans Hydrogen-Ion Concentration Iron blood Ligands Mathematics Oxygen blood Oxyhemoglobins Protein Binding Spectrum Analysis 1975 10 27 1975 10 27 0 1 1975 10 27 0 0 ppublish 6 0006-291X(75)90518-5 10.1016/0006-291x(75)90518-5 7 1976 01 26 2020 02 25

1873-2968 24 16 1975 Aug 15 Biochem Pharmacol Maturation of the adrenal medulla--IV. Effects of morphine. 1469-74 Anderson T R TR Slotkin T A TA eng MC_U147585819 MRC United Kingdom MC_UU_12011/1 MRC United Kingdom MC_UP_A620_1014 MRC United Kingdom Journal Article Research Support, U.S. Gov't, Non-P.H.S.

England Biochem Pharmacol 0101032 0006-2952 0 Catecholamines 76I7G6D29C Morphine 818U2PZ2EH Metaraminol EC 1.14.16.2 Tyrosine 3-Monooxygenase EC 1.14.17.1 Dopamine beta-Hydroxylase YKH834O4BH Epinephrine IM Adrenal Medulla enzymology growth & development metabolism Aging Animals Animals, Newborn Body Weight drug effects Catecholamines metabolism Dopamine beta-Hydroxylase metabolism Epinephrine metabolism Female Humans In Vitro Techniques Maternal-Fetal Exchange Metaraminol metabolism Morphine pharmacology Morphine Dependence metabolism Pregnancy Rats Tyrosine 3-Monooxygenase metabolism 1975 8 15 1975 8 15 0 1 1975 8 15 0 0 ppublish 7 0006-2952(75)90020-9 10.1016/0006-2952(75)90020-9 Br J Gen Pract. 1999 Oct;49(447):823-8 10885091 J Gastroenterol Hepatol. 2000 Oct;15(10):1093-9 11106086 Ann Intern Med. 2001 Jul 3;135(1):68-9 11434754 J Viral Hepat. 2001 Sep;8(5):358-66 11555193 BJOG. 2002 Mar;109(3):227-35 11950176 Drug Saf. 2002;25(5):323-44 12020172 Am J Med. 2002 Oct 15;113(6):506-15 12427501 J Altern Complement Med. 2003 Feb;9(1):161-8 12676044 Psychosomatics. 2003 Jul-Aug;44(4):271-82 12832592 Aliment Pharmacol Ther. 2003 Sep 1;18(5):451-71 12950418 Dig Dis Sci. 2003 Oct;48(10):1925-8 14627335 Cochrane Database Syst Rev. 2004;(1):CD002286 14973986 Mycoses. 2004 Apr;47(3-4):87-92 15078424 Planta Med. 2004 Apr;70(4):293-8 15095142 J Herb Pharmacother. 2004;4(1):49-67 15273078 J Herb Pharmacother. 2003;3(2):69-90 15277068 J Herb Pharmacother. 2003;3(1):121-33 15277076 J Herb Pharmacother. 2002;2(3):49-72 15277090 J Herb Pharmacother. 2002;2(1):71-85 15277109 J Herb Pharmacother. 2004;4(2):63-78 15364646 Expert Opin Pharmacother. 2004 Dec;5(12):2485-501 15571467 Drug Saf. 2005;28(4):319-32 15783241 Obstet Gynecol. 2005 Apr;105(4):849-56 15802416 J Herb Pharmacother. 2004;4(3):63-83 15829470 Obes Rev. 2005 May;6(2):93-111 15836459 Drug Saf. 2005;28(5):387-400 15853441 J Herb Pharmacother. 2004;4(4):61-90 15927926 Semin Arthritis Rheum. 2005 Jun;34(6):773-84 15942912 Expert Opin Drug Saf. 2005 Jul;4(4):779-94 16011454 J Herb Pharmacother. 2005;5(1):79-93 16093238 Complement Ther Med. 2005 Dec;13(4):279-90 16338199 Phytomedicine. 2006 May;13(5):371-7 16487688 J Herb Pharmacother. 2005;5(3):119-43 16520304 J Herb Pharmacother. 2005;5(4):71-114 16635970 Drug Saf. 2006;29(6):523-35 16752934 Mov Disord. 2006 Oct;21(10):1709-15 16830309 Eur Respir J. 2006 Aug;28(2):330-8 16880367 J Herb Pharmacother. 2006;6(1):89-126 17135164 J Herb Pharmacother. 2006;6(2):101-22 17182489 J Herb Pharmacother. 2006;6(3-4):135-59 17317655 Int J Toxicol. 2007;26 Suppl 1:3-106 17365137 Br J Psychiatry. 2007 May;190:379-84 17470951 Sleep Med Rev. 2007 Jun;11(3):209-30 17517355 J Herb Pharmacother. 2007;7(1):99-113 17594991 Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004559 17943819 Can J Physiol Pharmacol. 2007 Sep;85(9):837-47 18066129 World J Gastroenterol. 2008 Jan 21;14(3):454-62 18200670 Can J Clin Pharmacol. 2008 Winter;15(1):e66-73 18204101 J Herb Pharmacother. 2007;7(2):91-143 18285310 J Clin Epidemiol. 1991;44(11):1271-8 1834807 Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005288 18425916 Drug Saf. 2008;31(6):469-84 18484782 Cell Mol Neurobiol. 2009 Feb;29(1):17-25 18584321 J Herb Pharmacother. 2007;7(3-4):143-77 18928139 J Herb Pharmacother. 2007;7(3-4):279-323 18928148 Evid Based Complement Alternat Med. 2009 Mar;6(1):99-105 18955223 Am J Obstet Gynecol. 2008 Nov;199(5):455-66 18984078 Phytother Res. 2009 Apr;23(4):447-59 19086008 J Soc Integr Oncol. 2009 Spring;7(2):73-80 19476742 Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006568 19588398 Drug Saf. 2009;32(8):637-47 19591529 Curr Gastroenterol Rep. 2009 Aug;11(4):317-24 19615308 World J Gastroenterol. 2009 Oct 21;15(39):4886-95 19842218 Rev Recent Clin Trials. 2009 Sep;4(3):168-74 20028328 Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006556 20091597 Cardiovasc Hematol Agents Med Chem. 2010 Apr;8(2):113-27 20370653 Menopause. 2011 Apr;18(4):366-75 21228727 Planta Med. 2011 Jul;77(11):1149-60 21259185 Cochrane Database Syst Rev. 2011 Feb 16;(2):CD002948 21328257 Maturitas. 2011 Sep;70(1):37-41 21782365 J Psychiatr Res. 2011 Nov;45(11):1518-24 21820672 BMC Complement Altern Med. 2011 Aug 28;11:72 21871125 J Diet Suppl. 2010 Sep;7(3):283-302 22432518 J Diet Suppl. 2010 Dec;7(4):351-413 22432564 J Diet Suppl. 2011 Mar;8(1):58-114 22432635 J Diet Suppl. 2011 Jun;8(2):189-238 22432689 J Diet Suppl. 2011 Sep;8(3):311-30 22432729 J Diet Suppl. 2009;6(1):54-90 22435354 J Diet Suppl. 2009;6(2):162-200 22435415 J Diet Suppl. 2010 Jun;7(2):179-215 22435615 8 1976 01 26 2020 02 25

1873-2968 24 16 1975 Aug 15 Biochem Pharmacol Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase. 1517-21 Moroi K K Sato T T eng SF19107 Biotechnology and Biological Sciences Research Council United Kingdom Comparative Study Journal Article Published Erratum

England Biochem Pharmacol 0101032 0006-2952 0 Metals 0 Phospholipids 0 Proteins 34237V843T Isocarboxazid 4Z8Y51M438 Procaine EC 3.1.- Esterases EC 3.5.- Amidohydrolases IM Biochem Biophys Res Commun. 1975 Oct 27;66(4):1173-9 2 Amidohydrolases metabolism Animals Esterases metabolism Hydrogen-Ion Concentration In Vitro Techniques Isocarboxazid metabolism Kinetics Male Metals pharmacology Microsomes, Liver enzymology Phospholipids metabolism Procaine metabolism Proteins metabolism Rats Subcellular Fractions enzymology Temperature 1975 8 15 1975 8 15 0 1 1975 8 15 0 0 ppublish 8 0006-2952(75)90029-5 10.1016/0006-2952(75)90029-5 Nature. 2001 May 31;411(6837):599-603 11385576 Gastroenterology. 2003 Jul;125(1):47-57 12851870 Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):525-39 15157825 Gastroenterology. 2004 Oct;127(4):1051-7 15480983 N Engl J Med. 2004 Nov 11;351(20):2069-79 15537905 Nat Med. 2005 Apr;11(4):383-4 15812518 Int J Colorectal Dis. 2006 Dec;21(8):747-53 16228179 World J Gastroenterol. 2006 Apr 7;12(13):1991-9 16610046 Am J Gastroenterol. 2006 Jul;101(7):1559-68 16863561 Science. 2006 Dec 1;314(5804):1461-3 17068223 Int J Immunogenet. 2007 Jun;34(3):181-91 17504508 Nat Rev Genet. 2008 Jan;9(1):9-14 17968351 Nat Genet. 2008 Aug;40(8):955-62 18587394 Inflamm Bowel Dis. 2008 Nov;14(11):1469-82 18618634 Gut. 2008 Sep;57(9):1294-6 18719139 Nature. 2008 Nov 13;456(7219):259-63 18849966 Annu Rev Genomics Hum Genet. 2009;10:89-116 19453248 Inflamm Bowel Dis. 2009 Nov;15(11):1643-55 19462429 Nat Immunol. 2009 Oct;10(10):1073-80 19701189 Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15813-8 19805227 Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):513-34 19817673 Nat Immunol. 2010 Jan;11(1):55-62 19898471 Curr Gastroenterol Rep. 2009 Dec;11(6):481-7 19903424 Nat Med. 2010 Jan;16(1):90-7 19966812 Inflamm Bowel Dis. 2010 Jul;16(7):1108-17 20024904 Am J Gastroenterol. 2010 Aug;105(8):1811-9 20197757 Curr Opin Gastroenterol. 2010 Jul;26(4):327-31 20445446 J Immunol. 2010 Jun 15;184(12):7247-56 20483763 Inflamm Bowel Dis. 2011 Jan;17(1):346-61 20839313 Nat Genet. 2010 Dec;42(12):1118-25 21102463 Gastroenterology. 1989 Apr;96(4):1016-20 2925048 Gut. 1988 Jul;29(7):990-6 3396969 Nature. 1996 Feb 29;379(6568):821-3 8587604 Gastroenterology. 1996 Sep;111(3):597-603 8780562 Gut. 1996 Nov;39(5):690-7 9014768 9 1976 01 23 2019 06 23

0006-2952 24 17 1975 Sep 01 Biochem Pharmacol Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo. 1569-72 Marniemi J J Parkki M G MG eng Journal Article Research Support, U.S. Gov't, P.H.S.

England Biochem Pharmacol 0101032 0006-2952 0 Carrier Proteins 0 Epoxy Compounds 0 Styrenes 56-49-5 Methylcholanthrene EC 2.5.1.18 Glutathione Transferase GAN16C9B8O Glutathione YQE403BP4D Phenobarbital IM Animals Carrier Proteins metabolism Epoxy Compounds metabolism pharmacology Glutathione pharmacology Glutathione Transferase metabolism Hydrogen-Ion Concentration Liver enzymology Male Methylcholanthrene pharmacology Phenobarbital pharmacology Rats Stimulation, Chemical Styrenes pharmacology 1975 9 1 1975 9 1 0 1 1975 9 1 0 0 ppublish 9 0006-2952(75)90080-5 10.1016/0006-2952(75)90080-5 10 1976 01 23 2020 03 03

1873-2968 24 17 1975 Sep 01 Biochem Pharmacol Digitoxin metabolism by rat liver microsomes. 1639-41 Schmoldt A A Benthe H F HF Haberland G G eng K01 AG044439 AG NIA NIH HHS United States Journal Article

England Biochem Pharmacol 0101032 0006-2952 143-62-4 Digitoxigenin 53-59-8 NADP E90NZP2L9U Digitoxin IM Animals Chromatography, Thin Layer Digitoxigenin metabolism Digitoxin metabolism Hydroxylation In Vitro Techniques Male Microsomes, Liver metabolism NADP metabolism Rats Time Factors 1975 9 1 1975 9 1 0 1 1975 9 1 0 0 ppublish 10 0006-2952(75)90094-5 11 1976 01 23 2020 02 25

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Identification of adenylate cyclase-coupled beta-adrenergic receptors with radiolabeled beta-adrenergic antagonists. 1651-8 Lefkowitz R J RJ eng Journal Article Research Support, U.S. Gov't, P.H.S.

England Biochem Pharmacol 0101032 0006-2952 0 Adrenergic beta-Antagonists 0 Catecholamines 0 Receptors, Adrenergic 10028-17-8 Tritium 877K5MQ27W Alprenolol 9Y8NXQ24VQ Propranolol EC 4.6.1.1 Adenylyl Cyclases L628TT009W Isoproterenol IM Adenylyl Cyclases blood metabolism Adrenergic beta-Antagonists pharmacology Alprenolol blood Animals Anura Binding Sites Catecholamines pharmacology Cattle Cell Membrane enzymology Eels Erythrocytes enzymology Guinea Pigs In Vitro Techniques Isoproterenol pharmacology Kinetics Propranolol pharmacology Receptors, Adrenergic drug effects Stereoisomerism Tritium 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 11 0006-2952(75)90001-5 10.1016/0006-2952(75)90001-5 J Am Coll Cardiol. 2002 Jul 3;40(1):142-8 12103268 Postgrad Med J. 2005 Jul;81(957):442-7 15998820 Eur Heart J. 2006 Feb;27(3):344-50 16223744 Heart. 2006 Apr;92(4):559-68 16537784 Europace. 2006 Sep;8(9):746-837 16935866 Eur Heart J. 2007 Sep;28(18):2256-95 17726042 J Cardiovasc Electrophysiol. 2008 Jan;19(1):48-55 17916139 QJM. 2009 Jul;102(7):485-90 19474111 Eur Heart J. 2009 Nov;30(21):2631-71 19713422 Ann Intern Med. 1997 Jun 15;126(12):989-96 9182479 12 1976 01 23 2020 02 25

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells. 1659-62 Stein J M JM eng G1002528 Medical Research Council United Kingdom Journal Article

England Biochem Pharmacol 0101032 0006-2952 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Antagonists 0 Phosphorus Radioisotopes 0TTZ664R7Z Phenoxybenzamine 27YLU75U4W Phosphorus 8L70Q75FXE Adenosine Triphosphate 9Y8NXQ24VQ Propranolol EC 1.13.12.- Luciferases EC 2.7.1.1 Hexokinase YKH834O4BH Epinephrine IM Adenosine Triphosphate biosynthesis metabolism Adipose Tissue drug effects metabolism Adrenergic alpha-Antagonists pharmacology Adrenergic beta-Antagonists pharmacology Animals Epinephrine pharmacology Hexokinase pharmacology In Vitro Techniques Luciferases pharmacology Male Oxygen Consumption drug effects Phenoxybenzamine pharmacology Phosphorus metabolism Phosphorus Radioisotopes Propranolol pharmacology Rats Time Factors 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 12 0006-2952(75)90002-7 10.1016/0006-2952(75)90002-7 Int J Qual Health Care. 2007 Feb;19(1):50-5 17172600 Nurse Educ Pract. 2008 Sep;8(5):299-301 18692016 BMJ. 2009 Apr 21;338:b1555 19383750 BMJ. 2009 May 12;338:b1900 19435768 BMJ. 2011 Feb 03;342:c6646 21292716 BMJ. 2011 Sep 13;343:d5672 21914758 BMJ Qual Saf. 2012 Mar;21(3):234-8 22282817 Clin Med (Lond). 2012 Dec;12(6):520-5 23342404 BMJ Qual Saf. 2013 Aug;22(8):613-7 23661281 13 1976 01 23 2019 06 23

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin. 1701-5 Järvisalo J J Saris N E NE eng G9901400 Medical Research Council United Kingdom Journal Article

England Biochem Pharmacol 0101032 0006-2952 2001-95-8 Valinomycin 8L70Q75FXE Adenosine Triphosphate 9Y8NXQ24VQ Propranolol EC 3.6.1.- Adenosine Triphosphatases RRU6GY95IS Nigericin RWP5GA015D Potassium IM Adenosine Triphosphatases metabolism Adenosine Triphosphate pharmacology Animals Hydrogen-Ion Concentration In Vitro Techniques Mitochondria drug effects Mitochondria, Liver enzymology metabolism Mitochondrial Swelling drug effects Nigericin pharmacology Oxidative Phosphorylation drug effects Oxygen Consumption drug effects Potassium pharmacology Propranolol pharmacology Rats Time Factors Valinomycin pharmacology 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 13 0006-2952(75)90009-X 10.1016/0006-2952(75)90009-x 14 1976 01 23 2020 02 25

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Malathion A and B esterases of mouse liver-I. 1713-7 Bhagwat V M VM Ramachandran B V BV eng G0100165 Medical Research Council United Kingdom Journal Article

England Biochem Pharmacol 0101032 0006-2952 0 Metals 0 Sulfhydryl Compounds EC 3.1.- Esterases U5N7SU872W Malathion IM Animals Drug Stability Esterases analysis antagonists & inhibitors isolation & purification Female Hydrogen-Ion Concentration Liver enzymology ultrastructure Malathion metabolism Male Metals pharmacology Mice Sex Factors Sulfhydryl Compounds pharmacology 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 14 0006-2952(75)90011-8 10.1016/0006-2952(75)90011-8 Nature. 2003 Jan 2;421(6918):37-42 12511946 Proc Biol Sci. 2003 Sep 22;270(1527):1887-92 14561301 Nature. 2004 Jan 8;427(6970):145-8 14712274 Nature. 2006 Jan 12;439(7073):161-7 16407945 15 1976 01 23 2020 02 25

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Increase in acetyl CoA synthetase activity after phenobarbital treatment. 1725-7 Akamatsu N N Nakajima H H Ono M M Miura Y Y eng Journal Article

England Biochem Pharmacol 0101032 0006-2952 0 Proteins 98600C0908 Cycloheximide EC 2.6.1.16 Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) EC 2.7.- Phosphotransferases EC 3.1.1.6 Acetylesterase EC 6.2.1.- Coenzyme A Ligases EC 6.2.1.1 Acetate-CoA Ligase N08U5BOQ1K Glucosamine V956696549 Acetylglucosamine YQE403BP4D Phenobarbital IM Acetate-CoA Ligase metabolism Acetylesterase metabolism Acetylglucosamine Animals Coenzyme A Ligases metabolism Cycloheximide pharmacology Glucosamine Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) metabolism Liver drug effects enzymology Male Phenobarbital pharmacology Phosphotransferases metabolism Proteins metabolism Rats Stimulation, Chemical 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 15 0006-2952(75)90013-1 10.1016/0006-2952(75)90013-1 Clin Med (Lond). 2005 Jul-Aug;5(4):344-8 16138488 Arch Dis Child. 2007 Jul;92(7):573-5 17588971 Arch Dis Child. 2007 Dec;92(12):1143 18032643 Pediatrics. 2010 Nov;126(5):851-5 20956413 J Health Serv Res Policy. 2011 Apr;16(2):75-80 21389060 BMJ. 2011 Apr 18;342:d2421 21502273 Clin Med (Lond). 2011 Oct;11(5):420-1 22034695 Bull Hist Med. 1998 Summer;72(2):246-78 9628051 16 1976 01 23 2020 02 25

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. 1731-3 Turner A J AJ Hick P E PE eng Journal Article

England Biochem Pharmacol 0101032 0006-2952 0 Biogenic Amines 0 Pyrimidines 53-59-8 NADP EC 1.2.- Aldehyde Oxidoreductases X77S6GMS36 Homovanillic Acid IM Aldehyde Oxidoreductases antagonists & inhibitors Animals Biogenic Amines metabolism pharmacology Brain enzymology Homovanillic Acid pharmacology In Vitro Techniques Kinetics NADP Pyrimidines pharmacology Sheep 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 16 0006-2952(75)90016-7 10.1016/0006-2952(75)90016-7 J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 10690869 NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25 14768652 Endocr Rev. 2004 Apr;25(2):309-40 15082524 J Endocrinol Invest. 2006 Apr;29(4):298-302 16699294 N Engl J Med. 2007 Feb 8;356(6):601-10 17287480 Endocr Pract. 2008 Apr;14(3):279-84 18463033 Endocr Pract. 2009 Jul-Aug;15 Suppl 1:1-20 19632967 Endocrine. 2010 Feb;37(1):40-6 19882253 J Clin Endocrinol Metab. 2010 Sep;95(9):4106-13 20823463 Endocrine. 2011 Aug;40(1):80-3 21547511 Endocrine. 2011 Aug;40(1):134-6 21562920 Br J Surg. 2011 Oct;98(10):1383-91 21618498 Horm Metab Res. 2011 Dec;43(13):962-9 22048862 BMJ. 2012 May 28;344:e3502 22645185 17 1976 01 23 2020 03 04

0006-2952 24 18 1975 Sep 15 Biochem Pharmacol Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat. 1739-42 Renaud B B Buda M M Lewis B D BD Pujol J F JF eng HERU1 CSO_ Chief Scientist Office United Kingdom Journal Article

England Biochem Pharmacol 0101032 0006-2952 0 Catecholamines 0 Tryptamines EC 1.14.16.2 Tyrosine 3-Monooxygenase W2QY253O8S 5,6-Dihydroxytryptamine IM 5,6-Dihydroxytryptamine administration & dosage pharmacology Animals Brain enzymology Catecholamines physiology Cerebral Cortex enzymology Cisterna Magna Corpus Striatum enzymology In Vitro Techniques Injections Male Neurons enzymology Rats Rats, Inbred Strains Stimulation, Chemical Substantia Nigra enzymology Time Factors Tryptamines pharmacology Tyrosine 3-Monooxygenase metabolism 1975 9 15 1975 9 15 0 1 1975 9 15 0 0 ppublish 17 0006-2952(75)90018-0 10.1016/0006-2952(75)90018-0 BMJ. 2010 Apr 20;340:c2016 20406861 18 1976 01 29 2019 06 23

0006-2952 24 20 1975 Oct 15 Biochem Pharmacol Inhibition of aldehyde reductase isoenzymes in human and rat brain. 1865-9 Ris M M MM Deitrich R A RA Von Wartburg J P JP eng Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

England Biochem Pharmacol 0101032 0006-2952 0 Anticonvulsants 0 Barbiturates 0 Hydantoins 0 Isoenzymes 0 Succinimides 0U46U6E8UK NAD 53-59-8 NADP C8I4BVN78E Glutethimide EC 1.2.- Aldehyde Oxidoreductases IM Aldehyde Oxidoreductases antagonists & inhibitors Animals Anticonvulsants pharmacology Barbiturates pharmacology Brain enzymology Glutethimide pharmacology Humans Hydantoins pharmacology In Vitro Techniques Isoenzymes antagonists & inhibitors Kinetics NAD metabolism NADP pharmacology Rats Succinimides pharmacology 1975 10 15 1975 10 15 0 1 1975 10 15 0 0 ppublish 18 0006-2952(75)90405-0 10.1016/0006-2952(75)90405-0 19 1976 01 29 2020 02 25

0006-2952 24 20 1975 Oct 15 Biochem Pharmacol Antidepressant drugs affect dopamine uptake. 1896-7 Halaris A E AE Belendiuk K T KT Freedman D X DX eng Journal Article Research Support, U.S. Gov't, Non-P.H.S.

England Biochem Pharmacol 0101032 0006-2952 0 Antidepressive Agents 0 Central Nervous System Stimulants VTD58H1Z2X Dopamine IM Animals Antidepressive Agents pharmacology Brain drug effects metabolism Central Nervous System Stimulants pharmacology Depression, Chemical Dopamine metabolism In Vitro Techniques Male Rats 1975 10 15 1975 10 15 0 1 1975 10 15 0 0 ppublish 19 0006-2952(75)90412-8 10.1016/0006-2952(75)90412-8 JAMA. 2001 Jun 13;285(22):2871-9 11401608 Med Care. 2001 Aug;39(8 Suppl 2):II2-45 11583120 Health Serv Manage Res. 2002 May;15(2):126-37 12028801 Qual Saf Health Care. 2003 Dec;12(6):458-64 14645763 J Am Soc Nephrol. 2004 Mar;15(3):754-60 14978178 Lancet. 2004 Apr 3;363(9415):1147-54 15064036 BMJ. 2005 Apr 2;330(7494):781-3 15802723 J Am Coll Cardiol. 2005 Oct 4;46(7):1236-41 16198837 Milbank Q. 2005;83(4):691-729 16279964 JAMA. 2006 Jan 18;295(3):324-7 16418469 N Engl J Med. 2006 Nov 30;355(22):2308-20 17101617 J Eval Clin Pract. 2007 Apr;13(2):161-8 17378860 N Engl J Med. 2007 Aug 9;357(6):608-13 17687138 Qual Saf Health Care. 2007 Oct;16(5):387-99 17913782 BMJ. 2008 Jun 28;336(7659):1491-4 18577559 BMJ. 2008 Aug 13;337:a957 18703659 JAMA. 2008 Dec 24;300(24):2913-5 19109120 Clin Med (Lond). 2009 Apr;9(2):140-4 19435119 BMJ. 2009 Nov 19;339:b4809 19926689 BMJ. 2009 Nov 19;339:b4811 19926690 BMJ. 2010 Mar 31;340:c1234 20360220 BMJ. 2010 Apr 20;340:c2016 20406861 BMJ. 2010 Apr 23;340:c2153 20418546 N Engl J Med. 2010 Jul 1;363(1):45-53 20463332 BMJ. 2010 Aug 13;341:c4078 20709715 N Engl J Med. 2010 Dec 23;363(26):2477-81 21142528 J Am Soc Nephrol. 2011 Feb;22(2):225-34 21289212 BMJ. 2011 Feb 03;342:d199 21292720 Clin Med (Lond). 2010 Dec;10(6):537-9 21413472 Nephron Clin Pract. 2011;119(1):c10-7; discussion c17 21659780 Kidney Int. 2011 Nov;80(10):1021-34 21775971 Implement Sci. 2011 Oct 24;6:119 22024188 BMJ. 2012 Mar 01;344:e1001 22381521 Methods Inf Med. 2012;51(3):189-98 22476327 Ann Intern Med. 1998 Feb 15;128(4):289-92 9471932 Int J Qual Health Care. 1998 Oct;10(5):443-7 9828034 20 1976 01 29 2020 02 25

0006-2952 24 20 1975 Oct 15 Biochem Pharmacol Aggregation of blood platelets by adrenaline and its uptake. 1903-4 Barthel W W Markwardt F F eng Journal Article

England Biochem Pharmacol 0101032 0006-2952 436O5HM03C Dihydroergotamine 8NA5SWF92O Lysergic Acid Diethylamide YKH834O4BH Epinephrine IM Animals Blood Platelets metabolism Dihydroergotamine pharmacology Drug Interactions Epinephrine blood pharmacology In Vitro Techniques Lysergic Acid Diethylamide pharmacology Platelet Aggregation drug effects Rabbits 1975 10 15 1975 10 15 0 1 1975 10 15 0 0 ppublish 20 0006-2952(75)90415-3 10.1016/0006-2952(75)90415-3 Int J Qual Health Care. 2008 Feb;20(1):22-30 18073269 Qual Health Res. 2008 Mar;18(3):380-90 18235161 N Engl J Med. 2009 Jan 29;360(5):491-9 19144931 Med Educ. 1998 May;32(3):239-43 9743776 21 1976 01 26 2017 03 22

0004-4172 25 9 1975 Sep Arzneimittelforschung [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)]. 1352-4 (--)-alpha-Bisabolol has a primary antipeptic action depending on dosage, which is not caused by an alteration of the pH-value. The proteolytic activity of pepsin is reduced by 50 percent through addition of bisabolol in the ratio of 1/0.5. The antipeptic action of bisabolol only occurs in case of direct contact. In case of a previous contact with the substrate, the inhibiting effect is lost. Isaac O O Thiemer K K ger English Abstract Journal Article Biochemische Untersuchungen von Kamilleninhaltsstoffen. III. In-vitro-Versuche über die antipeptische Wirkung des (-)-alpha-Bisabolols

Germany Arzneimittelforschung 0372660 0004-4172 0 Hemoglobins 0 Sesquiterpenes 42HK56048U Tyrosine 5V2JDO056X Trichloroacetic Acid EC 3.4.23.1 Pepsin A IM Dose-Response Relationship, Drug Hemoglobins metabolism Hydrogen-Ion Concentration In Vitro Techniques Methods Pepsin A antagonists & inhibitors metabolism Plants, Medicinal Sesquiterpenes pharmacology Spectrophotometry, Ultraviolet Trichloroacetic Acid Tyrosine metabolism 1975 9 1 1975 9 1 0 1 1975 9 1 0 0 ppublish 21 22 1976 01 26 2020 02 25

0004-4172 25 9 1975 Sep Arzneimittelforschung [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities]. 1369-79 A report is given on the recent discovery of outstanding immunological properties in BA 1 [N-(2-cyanoethylene)-urea] having a (low) molecular mass M = 111.104. Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1.7 percent), results in a recovery rate of 40 percent without hyperglycemia and, in one test, of 80 percent with hyperglycemia. Under otherwise unchanged conditions the reference substance ifosfamide (IF) -- a further development of cyclophosphamide -- applied without hyperglycemia in its most efficient dosage of 47 percent LD50 (150 mg kg) brought about a recovery rate of 25 percent at a lethality of 18 percent. (Contrary to BA 1, 250-min hyperglycemia caused no further improvement of the recovery rate.) However this comparison is characterized by the fact that both substances exhibit two quite different (complementary) mechanisms of action. Leucocyte counts made after application of the said cancerostatics and dosages have shown a pronounced stimulation with BA 1 and with ifosfamide, the known suppression in the post-therapeutic interval usually found with standard cancerostatics. In combination with the cited plaque test for BA 1, blood pictures then allow conclusions on the immunity status. Since IF can be taken as one of the most efficient cancerostatics--there is no other chemotherapeutic known up to now that has a more significant effect on the DS carcinosarcoma in rats -- these findings are of special importance. Finally, the total amount of leucocytes and lymphocytes as well as their time behaviour was determined from the blood picture of tumour-free rats after i.v. application of BA 1. The thus obtained numerical values clearly show that further research work on the prophylactic use of this substance seems to be necessary and very promising. Ardenne M M Reitnauer P G PG ger Comparative Study English Abstract Journal Article Nachweis krebshemmender Eigenschaften einer stark immunstimulierenden Verbindung kleiner Molekülmasse. Versuche am immunlabilen DS-Karzinosarkom im Vergleich mit Ifosfamid. Stimulierung der körpereigenen Abwehr über etwa 20 Tage durch BA 1, einen N-(2-Cyanthylen)-harnstoff. Neue prophylaktische Möglichkeiten

Germany Arzneimittelforschung 0372660 0004-4172 0 Antineoplastic Agents 8N3DW7272P Cyclophosphamide 8W8T17847W Urea UM20QQM95Y Ifosfamide IM Animals Antineoplastic Agents pharmacology therapeutic use Carcinosarcoma drug therapy Cyclophosphamide analogs & derivatives Drug Evaluation, Preclinical Drug Tolerance Erythrocyte Count Hydrogen-Ion Concentration Hyperglycemia Ifosfamide pharmacology therapeutic use Immunity drug effects Immunosuppression Lethal Dose 50 Leukocyte Count Male Mice Neoplasms, Experimental drug therapy Rats Stimulation, Chemical Time Factors Urea analogs & derivatives pharmacology therapeutic use 1975 9 1 1975 9 1 0 1 1975 9 1 0 0 ppublish 22 Crit Care Med. 2006 Jul;34(7):1913-7 16715038 Crit Care. 2007;11(2):R31 17331245 J Am Soc Nephrol. 2010 Feb;21(2):345-52 20019168 Am J Kidney Dis. 2010 Oct;56(4):651-60 20673605 Blood Purif. 2010;30(2):120-6 20714143 Nephrol Dial Transplant. 2011 Jul;26(7):2161-8 21148028 Am J Kidney Dis. 2011 Feb;57(2):228-34 21195518 Clin J Am Soc Nephrol. 2012 Apr;7(4):533-40 22362062 QJM. 2012 Aug;105(8):729-40 22408153 Clin J Am Soc Nephrol. 2012 May;7(5):712-9 22422536 QJM. 2013 Apr;106(4):323-32 23345468 J R Coll Physicians Edinb. 2013;43(1):37-8 23516690 23 1976 01 26 2020 02 25

0004-4172 25 9 1975 Sep Arzneimittelforschung Effect of etafenone on total and regional myocardial blood flow. 1400-3 The distribution of blood flow to the subendocardial, medium and subepicardial layers of the left ventricular free wall was studied in anaesthetized dogs under normoxic (A), hypoxic (B) conditions and under pharmacologically induced (etafenone) coronary vasodilation (C). Regional myocardial blood flow was determined by means of the particle distribution method. In normoxia a transmural gradient of flow was observed, with the subendocardial layers receiving a significantly higher flow rate compared with the subepicardial layers. In hypoxia induced vasodilation this transmural gradient of flow was persistent. In contrast a marked redistribution of regional flow was observed under pharmacologically induced vasodilation. The transmural gradient decreased. In contrast to some findings these experiments demonstrate that a considerable vasodilatory capacity exists in all layers of the myocardium and can be utilized by drugs. The differences observed for the intramural distribution pattern of flow under hypoxia and drug induced vasodilation support the hypothesis that this pattern reflects corresponding gradients of regional myocardial metabolism. Flohr H H Breull W W eng G0700399 Medical Research Council United Kingdom Journal Article

Germany Arzneimittelforschung 0372660 0004-4172 0 Propiophenones 0 Vasodilator Agents 142M471B3J Carbon Dioxide S88TT14065 Oxygen IM Animals Blood Pressure drug effects Carbon Dioxide blood Cardiac Output drug effects Coronary Circulation drug effects Coronary Vessels drug effects Dogs Heart Rate drug effects Heart Septum Heart Ventricles Hydrogen-Ion Concentration Hypoxia physiopathology Oxygen blood Propiophenones pharmacology Vasodilator Agents pharmacology 1975 9 1 1975 9 1 0 1 1975 9 1 0 0 ppublish 23 J Appl Psychol. 2001 Aug;86(4):730-40 11519656 South Med J. 2005 May;98(5):528-32 15954509 J Crit Care. 2008 Jun;23(2):167-72 18538207 Med Educ. 2009 Jan;43(1):50-7 19140997 Clin Med (Lond). 2009 Oct;9(5):417-20 19886098